Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
